Inhaled NO and markers of oxidant injury in infants with respiratory failure

Journal of Perinatology

Volumn 25, Issue 7, 2005, Pages 463-469

  Van Meurs, Krisa P ^a   Cohen, Toby L ^e   Yang, Guang ^c   Somaschini, Marco ^b   Kuruma, Pavani ^a   Dennery, Phyllis A ^c,d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOLOGNINI HOSPITAL   (Italy)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e Aurora Baycare Medical Center Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; CARBONYL DERIVATIVE; GLUTATHIONE; LIPID HYDROPEROXIDE; NITRIC OXIDE; OXYGEN;

AMBIENT AIR; ARTICLE; CHRONIC LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; EXPOSURE; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PREDICTION; PROSPECTIVE STUDY; PROTEIN CONTENT; RESPIRATORY FAILURE;

ADMINISTRATION, INHALATION; BIOLOGICAL MARKERS; BRONCHODILATOR AGENTS; CHRONIC DISEASE; FEMALE; GLUTATHIONE; HUMANS; INFANT, NEWBORN; LIPID PEROXIDES; MALE; NITRIC OXIDE; OXIDATIVE STRESS; PROSPECTIVE STUDIES; RESPIRATORY DISTRESS SYNDROME, NEWBORN; TYROSINE;

EID: 22144473637     PISSN: 07438346     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jp.7211327     Document Type: Article

References (29)

1. Davis JM, Spitzer AR, Cox C, Fox WW. Predicting survival in infants with persistent pulmonary hypertension of the newborn. Pediatr Pulmonol 1988;5:6-9.
2. Hageman JR, Dusik J, Keuler H, Bregman J, Gardner TH. Outcome of persistent pulmonary hypertension in relation to severity of presentation. Am J Dis Child 1988;142:293-6.
3. Gersony WM. Neonatal pulmonary hypertension: pathophysiology, classification, and etiology. Clin Perinatol 1984;11:517-24.
4. Roberts JD, Fineman JR, Morin FC, et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. N Engl J Med 1997;336:605-610.
5. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med 1997;336:597-604.
6. Clark RH, Kueser TJ, Walker MW, et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. N Engl J Med 2000;342:469-74.
7. Austin AT. The chemistry of the higher oxides of nitrogen as related to the manufacture, storage and administration of nitrous oxide. Br J Anaesth 1967;39:345-50.
8. Foubert L, Fleming B, Latimer R, et al. Safety guidelines for use of nitric oxide [letter] [see comments]. Lancet 1992;339:1615-6.
9. Robbins CG, Horowitz S, Merritt TA, et al. Recombinant human superoxide dismutase reduces lung injury caused by inhaled nitric oxide and hyperoxia. Am J Physiol 1997;272:L903-7.
10. Gutierrez HH, Nieves B, Chumley P, Rivera A, Freeman BA. Nitric oxide regulation of superoxide-dependent lung injury: oxidant-protective actions of endogenously produced and exogenously administered nitric oxide. Free Radic Biol Med 1996;21:43-52.
11. Storme L, Zerimech F, Riou Y, et al. Inhaled nitric oxide neither alters oxidative stress parameters nor induces lung inflammation in premature lambs with moderate hyaline membrane disease. Biol. Neonate 1998;73:172-81.
12. Lorch SA, Banks BA, Christie J, et al. Plasma 3-nitrotyrosine and outcome in neonates with severe bronchopulmonary dysplasia after inhaled nitric oxide. Free Radic Biol Med 2003;34:1146-52.
13. Haddad IY, Pataki G, Hu P, et al. Quantitation of nitrotyrosine levels in lung sections of patients and animals with acute lung injury. J Clin Invest 1994;94:2407-13.
14. Ohishi N, Ohkawa H, Miike A, Tatana T, Yagi K. A new assay method for lipid peroxides using a methylene blue derivative. Biochem Int 1985;10:205-11.
15. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990;87:1620-4.
16. Halliwell B. Oxidants and human disease: some new concepts. FASEB J 1987;1:358-64.
17. Kinsella JP, Parker TA, Galan H, Sheridan BC, Halbower AC, Abman SH. Effects of inhaled nitric oxide on pulmonary edema and lung neutrophil accumulation in severe experimental hyaline membrane disease. Pediatr Res 1997;41:457-63.
18. Ben Baouali A, Aube H, Maupoil V, Blettery B, Rochette L. Plasma lipid peroxidation in critically ill patients: importance of mechanical ventilation. Free Radic Biol Med 1994;16:223-7.
19. Kokk T, Talvik R, Zilmer M, Kutt E, Talvik T. Markers of oxidative stress before and after exchange transfusion for neonatal sepsis. Acta Paediatr 1996;85:1244-6.
20. Dominguez C, Ruiz E, Gussinye M, Carrascosa, A. oxidative stress at onset and in early stages of type 1 diabetes in children and adolescents. Diabetes Care 1998;21:1736-42.
21. Inouye M, Hashimoto H, Mio T, Sumino K. Levels of lipid peroxidation product and glycated hemoglobin A1c in the erythrocytes of diabetic patients. Clin Chim Acta 1998;276:163-72.
22. Jornot L, Junod AF. Variable glutathione levels and expression of antioxidant enzymes in human endothelial cells. Am J Physiol 1993; 264;L482-9.
23. Kennedy KA, Lane NL. Effect of in vivo hyperoxia on the glutathione system in neonatal rat lung. Exp Lung Res 1994;20: 73-83.
24. Ho YS, Dey MS, Crapo JD. Antioxidant enzyme expression in rat lungs during hyperoxia. Am J Physiol 1996;270:L810-8.
25. Silvers KM, Gibson AT, Russell JM, Powers HJ. Antioxidant activity, packed cell transfusions, and outcome in premature infants. Arch Dis Child Fetal Neonatal Ed 1998;78:F214-9.
26. Gladstone Jr IM, Levine RL. Oxidation of proteins in neonatal lungs. Pediatrics 1994;93:764-8.
27. Varsila E, Pitkanen O, Hallman M, Andersson S. Immaturity-dependent free radical activity in premature infants. Pediatr Res 1994;36:55-9.
28. Winterbourn CC, Chan T, Buss IH, Inder TE, Mogridge N, Darlow BA. Protein carbonyls and lipid peroxidation products as oxidation markers in preterm infant plasma: associations with chronic lung disease and retinopathy and effects of selenium supplementation. Pediatr Res 2000;48:84-90.
29. Banks BA, Ischiropoulos H, McClelland M, Ballard PL, Ballard RA. Plasma 3-nitrotyrosine is elevated in premature infants who develop bronchopulmonary dysplasia. Pediatrics 1998;101:870-4.